LD013 / Nanjing Blue Shield Biotech - LARVOL DELTA

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer (clinicaltrials.gov) - P=N/A | N=3 | Completed | Sponsor: Weijia Fang, MD | Recruiting ➔ Completed | Trial completion date: Feb 2026 ➔ Feb 2023

Trial completion • Trial completion date • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • MSLN

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer (clinicaltrials.gov) - P=N/A | N=9 | Recruiting | Sponsor: Weijia Fang, MD

CAR T-Cell Therapy • New trial • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • MSLN